(BUSINESS WIRE)--At next week’s American Society of Clinical Oncology Meeting, Pfizer will present new information that underscores the depth and breadth of its oncology portfolio and the significant potential of projects advancing through the company’s research and development pipeline.
Note: Details about key Pfizer presentations at ASCO are in the accompanying press release.
Pfizer’s R&D pipeline in oncology is robust, with active programs in immunotherapy, signal transduction inhibition, and angiogenesis inhibition.
-- During the past 5 years, the number of R&D oncology projects in Pfizer has increased four-fold. -- In 2007, Pfizer Global Research & Development is conducting 212 oncology studies. -- Pfizer has 15 oncology compounds in clinical development. -- Pfizer has 3 compounds in phase III and 4 compounds in phase II. -- Pfizer's growing oncology strength is demonstrated by over 52 abstracts to be presented at ASCO this year (26 in 2006). -- 33 Sutent abstracts will be presented (17 in 2006). -- Today, Pfizer is investing more than 20 percent of its development budget to oncology. -- Through its newly-established Oncology Therapeutic Area, Pfizer is able to focus resources on the areas of greatest unmet need and deliver innovative products faster for patients and physicians who care for them.
In 2006, Pfizer’s currently marketed products -- including Camptosar, Aromasin, Sutent -- accounted for approximately $1.9 billion in revenues, an increase of 18 percent in one year.